A new invention patent "A Process Control Method for the Preparation of Lysine Acetate" attained by Proudin

Recently, Yichang Sanxia Proudin Biopharmaceutical Co., Ltd. received the "Notice of Granting Invention Patent" from China National Intellectual Property Administration, that the invention application "A Process Control Method for the Preparation of Lysine Acetate" by our company was noticed for granted, after the registration procedures, we will receive the letter of patent. This is the first invention patent we have that granted by our independent research since demerged. In addition to the "Synthesis Method of Carbocisteine" and "Concentration System and Method for Isoleucine Extraction Process" which have been granted before demerged and transferred to our company, we have 3 invention patents granted for now.   

Proudin has been working intensively in the field of amino acids for decades years and has accumulated abundant experience. We attaches great importance to R&D and intellectual property protection, and encourages innovation. Proudin have formed a whole set of intellectual property management system, and obtained the "Intellectual Property Management System Certification" (GB/T29490-2013) in 2021. At present, our patent map mainly focuses on the improvement of amino acid production equipments and processes, and now we have 29 patents ( invention and utility model).

The new granted invention patent refers to a production process of lysine acetate. The process of the invention can monitor and control each step more directly and accurately, and improve the product purity. Lysine acetate is mainly used to supplement lysine, which is one of the essential amino acids in the human body. Lysine is the first restricted amino acid, which can promote human development, enhance immune function, and improve the function of central nervous system. When lysine is lacking, symptoms such as anorexia, malnutrition, growth retardation, nutritional anemia, and osteoporosis will occur, and it will also affect the development of the central nervous system, resulting in mental retardation and unresponsiveness in children. As lysine itself is unstable in the environment, mostly it is made in the form of lysine salts, such as lysine hydrochloride and lysine acetate.

Lysine acetate can be used in medicine to prepare amino acid injections and oral preparations, and can also be used as an auxiliary drug for diuretics to treat lead poisoning caused by the reduction of chloride in the blood; it can react with acidic drugs (such as salicylic acid, etc.) to generate salt to relieve adverse reactions.

In addition to infusions and special functional milk powder on the market, α-keto acid tablets and dexamethasone eye drops also use lysine acetate as a formula ingredient. Moreover, due to the side effects of chloride ions in lysine hydrochloride, the tendency of lysine acetate to replace lysine hydrochloride in medicine and food is apparent in the future.

In the current, Proudin's annual production capacity of lysine acetate can reach 500 tons, and the product quality can reach EP10, USP43, CP and other standards. In the production process of the product, the raw materials and technological process are strictly controlled, and the high-performance liquid chromatography, amino acid analyzer and other precision instruments are used to accurately test the product quality, which can meet the ideal quality requirements.

The lysine acetate produced by Proudin has a superior position in the premium market. From January 2019 to March 2022, the proportion of Proudin in the total export amount of lysine acetate in China ranked first. The granting of the present invention patent will encourage us to further improve the market competitiveness of this product by making full use of the superiority of technolog. Lysine acetate is our core product, in the follow-up, we will take advantage of cost and quality to further cultivate and master the core technology; further, Proudin will upgrade the quality and system of all products to meet the requirements of domestic and European and American premium markets.